Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases

Clinical and Translational Oncology

Volumn 12, Issue 8, 2010, Pages 568-573

  López Carrizosa, María Concepción ^a   Samper Ots, Pilar María ^a   Pérez, Aurora Rodríguez ^a  

^a HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

Bone metastases; C telopeptides; Skeletal related events; Zoledronic acid

Indexed keywords

CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; PARACETAMOL; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BLADDER TUMOR; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST TUMOR; CANCER CONTROL; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSPECTIVE STUDY; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; SOLID TUMOR; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASMS; PEPTIDES; PROGNOSIS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77958191397     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0555-z     Document Type: Article

References (27)

1. R.E. Coleman 2006 Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s 6249s 10.1158/1078-0432.CCR-06- 0931 17062708 (Pubitemid 44703797)
2. G.R. Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 584 593 1:CAS:528:DC%2BD38XlslGqsLo%3D 10.1038/nrc867 12154351 (Pubitemid 37328925)
3. R.E. Coleman 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165 176 1:CAS:528:DC%2BD3MXktlCktb4%3D 10.1053/ctrv.2000.0210 11417967 (Pubitemid 32452017)
4. Mundy GR, Guise TA (2000) Pathophysiology of bone metastasis. In: Cancer and the skeleton, Third Edition (Rubens RD, Mundy GR, eds), pp 43-64. London: Informa Health Care.
5. U. Ulrich K. Rhiem J. Schmolling, et al. 2001 Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer Arch Gynecol Obstet 264 186 190 1:CAS:528:DC%2BD3MXlsVSqsQ%3D%3D 10.1007/s004040000105 11205705 (Pubitemid 32105009)
6. A. Lipton L. Costa S. Ali, et al. 2001 Use of markers of bone turnover for monitoring bone metastases and the response to therapy Semin Oncol 28 54 59 1:STN:280:DC%2BD3MvpsFyntg%3D%3D 10.1016/S0093-7754(01)90233-7 11544577 (Pubitemid 32844930)
7. P.D. Delmas A. Schlemmer E. Gineyts, et al. 1991 Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis J Bone Miner Res 6 639 644 1:STN:280:DyaK3MzmtFyqtw%3D%3D 10.1002/jbmr.5650060615 1887826
8. K.L. Kavanagh K. Guo J.E. Dunford, et al. 2006 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci U S A 103 7829 7834 1:CAS:528:DC%2BD28XlsVGksL0%3D 10.1073/pnas.0601643103 16684881 (Pubitemid 43752866)
9. L. Widler K.A. Jaeggi M. Glatt, et al. 2002 Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa) J Med Chem 45 3721 3738 1:CAS:528:DC%2BD38Xltl2jtLw%3D 10.1021/jm020819i 12166945 (Pubitemid 34863233)
10. J. Yu S.S. Chang S. Suratwala, et al. 2005 Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC) J Orthop Res 23 1004 1012 1:CAS:528:DC%2BD2MXpslygsL0%3D 10.1016/j.orthres.2005.02.012 15921873 (Pubitemid 41245422)
11. J.R. Green 2003 Antitumor effects of bisphosphonates Cancer 97 840 847 10.1002/cncr.11128 12548584
12. L.S. Rosen D. Gordon M. Kaminski, et al. 2001 Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 377 387 1:STN:280:DC%2BD3Mnjs1yqtQ%3D%3D 11693896 (Pubitemid 33759002)
13. L.S. Rosen D. Gordon S. Tchekmedyian, et al. 2003 Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 3150 3157 1:CAS:528:DC%2BD2cXpsVWqtb0%3D 10.1200/JCO.2003.04.105 12915606 (Pubitemid 46606297)
14. F. Saad D.M. Gleason R. Murray, et al. 2002 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458 1468 1:CAS:528:DC%2BD38XosVans7g%3D 12359855
15. R. Coleman J. Brown E. Terpos, et al. 2008 Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions Cancer Treat Rev 34 629 639 1:CAS:528:DC%2BD1cXht1KgtrvL 10.1016/j.ctrv.2008.05.001 18579314
16. N. Kohno K. Aogi H. Minami, et al. 2005 Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J Clin Oncol 23 3314 3321 1:CAS:528:DC%2BD2MXlsVyiu7w%3D 10.1200/JCO.2005.05.116 15738536 (Pubitemid 46243475)
17. A. Lipton R.J. Cook R.E. Coleman, et al. 2007 Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma Clin Lymphoma Myeloma 7 346 353 1:CAS:528:DC%2BD2sXlslKltbg%3D 10.3816/CLM.2007.n.011 17562244 (Pubitemid 46725236)
18. J.E. Brown C.S. Thomson S.P. Ellis, et al. 2003 Bone resorption predicts for skeletal complications in metastatic bone disease Br J Cancer 89 2031 2037 1:STN:280:DC%2BD3srmsFKrug%3D%3D 10.1038/sj.bjc.6601437 14647134 (Pubitemid 38030899)
19. A. Lipton L. Demers E. Curley, et al. 1998 Markers of bone resorption in patients treated with pamidronate Eur J Cancer 34 2021 2026 1:CAS:528: DyaK1MXitVWhtw%3D%3D 10.1016/S0959-8049(98)00277-9 10070304 (Pubitemid 28546935)
20. H.D. Menssen A. Sakalova A. Fontana, et al. 2002 Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma J Clin Oncol 20 2353 2359 1:CAS:528:DC%2BD38XktVKrs7k%3D 10.1200/JCO.2002.02.032 11981007 (Pubitemid 34441663)
21. J.E. Brown R.J. Cook P. Major, et al. 2005 Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 59 69 1:CAS:528:DC%2BD2MXisVarsA%3D%3D 10.1093/jnci/dji002 15632381
22. A. Lipton R.J. Cook P. Major, et al. 2007 Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity Oncologist 12 1035 1043 1:CAS:528:DC%2BD2sXht1Krs73O 10.1634/theoncologist.12-9-1035 17914073 (Pubitemid 350007015)
23. K. Jung M. Lein M. Ringsdorf, et al. 2006 Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma J Urol 176 1326 1331 10.1016/j.juro.2006.06.028 16952623 (Pubitemid 44307214)
24. M. Clemons G. Dranitsaris D. Cole, et al. 2006 Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer Oncologist 11 227 233 1:CAS:528: DC%2BD28XhtFKlsbzN 10.1634/theoncologist.11-3-227 16549806
25. UK Clinical Research Network (2009) Cost-effective use of BISphosphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule - The BISMARK Trial. Available at: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=1737 (accessed on June, 2009).
26. NCI (2007) Randomized Study of Bone Marker-Directed Schedule Versus Standard Schedule of Zoledronic Acid in Patients With Advanced Breast Cancer Metastatic to the Bone. Available at: http://www.cancer.gov/search/ViewClinical- Trials.aspx?cdrid=538879&version=HealthProfessional&protocolsearchid= 6240196 (accessed on June, 2009).
27. B.E. Hillner J.N. Ingle J.R. Berenson, et al. 2000 American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel J Clin Oncol 18 1378 1391 1:STN:280:DC%2BD3c7otF2jtg%3D%3D 10715310